PEG-MGF: reported timelines in the literature
A research-supply summary of PEG-MGF (pegylated mechano growth factor), covering its formal nomenclature, the IGF-1 axis it is studied against, and the reported timelines from the available literature. For laboratory res
PEG-MGF: reported timelines in the literature
PEG-MGF is the pegylated form of mechano growth factor (MGF), also referred to in the literature as IGF-1Ec, a splice variant of the insulin-like growth factor-1 (IGF-1) gene. It is supplied as a lyophilised research peptide and is handled in laboratory settings as a tool compound for studying the GH-IGF-1 axis. The evidence block available for this page does not provide a sequence, molecular formula, or molecular weight for PEG-MGF, so none are stated here. The compound is catalogued as PEG-MGF for research use only.
The work around this compound centres on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine pathway that governs somatic growth, tissue repair signalling, and a range of metabolic readouts in laboratory models [1].
Research Studies
PEG-MGF and the GH-IGF-1 axis in performance-enhancing peptide reviews
A review of performance-enhancing peptides that modulate the GH-IGF-1 axis describes the agents most commonly encountered in clinical practice and in online self-administration protocols. The review lists GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without DAC), growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604 (hGH 176-191), and IGF-1 analogues [1]. PEG-MGF is not named individually in the quoted passage, but it sits within the IGF-1 analogue class that the review identifies as part of this emerging landscape. The review frames these materials as unregulated peptides marketed as research compounds, and it does not report a timeline for any of them [1].
PEG-MGF and pegylated growth hormone comparators in paediatric studies
The closest clinical timeline data in the evidence block comes from a study of PEG-somatropin (pegylated recombinant human growth hormone, PEG-rhGH) in children with Turner syndrome. That trial was designed to explore the optimal dose of PEG-rhGH, to preliminarily evaluate safety and efficacy, and to provide evidence for a Phase 3 medication dosage [8]. The study population was children with Turner syndrome, not adults, and the compound was PEG-rhGH, not PEG-MGF. No timeline for PEG-MGF itself is reported in that record. The comparison is included here only because it is the sole pegylated growth-hormone-axis intervention in the evidence block with a stated clinical study design.
| Compound | Population | Study type | Reported timeline |
|---|---|---|---|
| PEG-rhGH (PEG-somatropin) | Children with Turner syndrome | Dose-finding, safety and efficacy, pre-Phase 3 | Not stated in the evidence block [8] |
| PEG-MGF | Not reported | Not reported | Not reported in the evidence block |
PEG-MGF and the absence of named timelines in the peptide review
The performance-enhancing peptide review does not attach a timeline to any of the compounds it lists, including the IGF-1 analogues [1]. It describes the class, the clinical and online contexts in which the agents appear, and the regulatory gap between clinical evidence and self-administration. For PEG-MGF specifically, the review provides no onset, duration, or clearance figures. Any timeline claim for PEG-MGF would therefore have to come from a source outside this evidence block, and none is available here.
PEG-MGF and adjacent Alzheimer's disease trial timelines
Several records in the evidence block describe long-duration trials in early Alzheimer's disease, and they are included here only to illustrate how timelines are reported for other compounds in the same repository. The EVOKE study of semaglutide in early Alzheimer's disease was planned to last up to 173 weeks (about 3 years and 4 months), with 17 clinic visits and 1 phone call, and blood samples at 10 of the clinic visits [4]. The EVOKE Plus study used the same 173-week duration and the same visit schedule [5]. A trial of trontinemab in early symptomatic Alzheimer's disease assessed efficacy and safety in participants with mild cognitive impairment to mild dementia due to Alzheimer's disease [2], and a separate pre-screening study assessed potential eligibility for Roche interventional Alzheimer's disease studies [3]. None of these records involve PEG-MGF, and none report a timeline for it.
| Study | Compound | Population | Reported duration |
|---|---|---|---|
| EVOKE [4] | Semaglutide vs placebo | Early Alzheimer's disease | Up to 173 weeks (about 3 years 4 months) |
| EVOKE Plus [5] | Semaglutide vs placebo | Early Alzheimer's disease | Up to 173 weeks (about 3 years 4 months) |
| Trontinemab trial [2] | Trontinemab | Early symptomatic Alzheimer's disease | Not stated in the evidence block |
| Pre-screening study [3] | Not applicable | Potential Alzheimer's disease trial participants | Not stated in the evidence block |
PEG-MGF and cardiovascular epidemiology timelines
A study of lipoprotein(a) in patients with established cardiovascular disease was conducted to improve knowledge about the epidemiology of lipoprotein(a) in that population [6]. A separate trial, THALES, investigated whether ticagrelor and ASA were more effective than placebo and ASA in preventing new stroke events after acute stroke or transient ischaemic attack [7]. Neither record involves PEG-MGF, and neither reports a timeline for it. They are listed here because they are part of the evidence block and because they show the range of study designs in which timeline data are reported for other compounds.
PEG-MGF and the limits of the available evidence
The evidence block does not contain a study of PEG-MGF in any model. There is no animal-only study, no in vitro study, and no human study of PEG-MGF in the sources provided. The review of performance-enhancing peptides discusses the IGF-1 analogue class as a whole and does not single out PEG-MGF for timeline reporting [1]. The pegylated growth hormone study in Turner syndrome children concerns PEG-rhGH, a different molecule [8]. Consequently, no onset, peak, or duration figures for PEG-MGF can be stated from this evidence block. Any timeline a reader encounters elsewhere should be checked against its primary source, because the sources here do not supply one.
PEG-MGF and the regulatory context of research peptides
The peptide review notes that performance-enhancing drugs marketed as research compounds include unregulated peptides intended to modulate the GH-IGF-1 axis, and that these agents appear both in clinical practice and in online self-administration protocols [1]. That framing is relevant to how timelines are reported: for a compound without a registered clinical programme, timeline information tends to circulate outside peer-reviewed sources. The evidence block contains no registered trial of PEG-MGF, so no timeline from a registered study can be cited here.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for personal use.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
- [2] A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease. https://clinicaltrials.gov/study/NCT07170150
- [3] Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies. https://clinicaltrials.gov/study/NCT07177352
- [4] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). https://clinicaltrials.gov/study/NCT04777396
- [5] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). https://clinicaltrials.gov/study/NCT04777409
- [6] Lipoprotein(a) in Patients With Cardiovascular Disease (CVD). https://clinicaltrials.gov/study/NCT03887520
- [7] THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death. https://clinicaltrials.gov/study/NCT03354429
- [8] A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome. https://clinicaltrials.gov/study/NCT03189160